Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

CapTCR-seq: hybrid capture for T-cell receptor repertoire profiling.

Mulder DT, Mahé ER, Dowar M, Hanna Y, Li T, Nguyen LT, Butler MO, Hirano N, Delabie J, Ohashi PS, Pugh TJ.

Blood Adv. 2018 Dec 11;2(23):3506-3514. doi: 10.1182/bloodadvances.2017014639. Erratum in: Blood Adv. 2019 Jan 22;3(2):121.

2.

Target oxygen saturation and development of pulmonary hypertension and increased pulmonary vascular resistance in preterm infants.

Laliberté C, Hanna Y, Ben Fadel N, Lemyre B, Bijelic V, Barrowman N, Hoey L, Thébaud B, Katz SL.

Pediatr Pulmonol. 2019 Jan;54(1):73-81. doi: 10.1002/ppul.24193. Epub 2018 Nov 20.

PMID:
30461218
3.

Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors.

Yang SYC, Lheureux S, Karakasis K, Burnier JV, Bruce JP, Clouthier DL, Danesh A, Quevedo R, Dowar M, Hanna Y, Li T, Lu L, Xu W, Clarke BA, Ohashi PS, Shaw PA, Pugh TJ, Oza AM.

Genome Med. 2018 Oct 31;10(1):81. doi: 10.1186/s13073-018-0590-x.

4.

Optimal specific wavelength for maximum thrust production in undulatory propulsion.

Nangia N, Bale R, Chen N, Hanna Y, Patankar NA.

PLoS One. 2017 Jun 27;12(6):e0179727. doi: 10.1371/journal.pone.0179727. eCollection 2017.

5.

Maternal adaptation to vasculogenesis and angiogenesis at the feto-maternal interface.

Yagel S, Goldman-Wohl DS, Mandelboim O, Hanna Y, Hochner-Celnikier D.

Thromb Res. 2005 Feb;115 Suppl 1:97-9. No abstract available.

PMID:
15790169
6.

Acute and subacute toxicity associated with concurrent adjuvant radiation therapy and paclitaxel in primary breast cancer therapy.

Hanna YM, Baglan KL, Stromberg JS, Vicini FA, A Decker D.

Breast J. 2002 May-Jun;8(3):149-53.

PMID:
12047471
7.

Bromodeoxyuridine improves the cytotoxic effect of cisplatin: a comparison with 5-fluorouracil.

Chelladurai M, Lobocki CA, Sultani M, Hanna Y, Drelichman A, Pieper DR, McLaughlin PW.

Cancer Chemother Pharmacol. 1997;40(6):463-8.

PMID:
9332459

Supplemental Content

Support Center